KAZIA THERAPEUTICS LIMITED.
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Novogen becomes Kazia Therapeutics 2017-11-20 14:21
Australian cancer specialists may hold key to next advancement in ovarian cancer treatment 2017-08-31 06:00
GDC-0084 Progress Update: On Track for Phase II Commencement in 2017 2017-08-22 12:06
Board Review of Business Operations and Governance 2017-08-14 11:02
Progress Update on Cantrixil(TM) (TRXE-002-1) Development 2017-08-07 11:03
Transformation to a Clinical Stage Organisation Leads to Changes in Management Structure 2017-03-10 09:21
Novogen Awarded Grant of up to A$3m by Australian Federal Government for Novel Drug Discovery Program 2017-03-06 18:54
Novogen Acquires Privately-held Neuro-oncology Company to Support Development of GDC-0084 in Glioblastoma 2016-10-31 11:54
Novogen Licenses Phase II-Ready Molecule from Genentech for Development in Glioblastoma 2016-10-31 11:40
Conversion of Convertible Notes 2016-09-14 12:07
US FDA Approves Investigational New Drug (IND) Application for Cantrixil(TM) (TRX-E-002-1) in Ovarian Cancer 2016-09-12 11:00
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in Ovarian Cancer 2016-08-11 13:59
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant 2016-06-14 08:30
Novogen Provides Update On Development Of Cantrixil 2016-05-02 10:43
Novogen Receives R&D Tax Incentive Cash Refund 2016-03-17 10:27
Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant 2016-02-19 14:18
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed 2016-02-05 15:31
Novogen Appoints Dr James Garner as Chief Executive Officer 2015-12-10 06:02
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial 2015-11-24 08:38
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia 2015-11-12 08:04
1 2 3 4 5 6 7